Pterostilbene, PQQ, Astaxanthin (Niche Polyphenols / Quinones)

Verdict: Mostly hype (all three, with minor variation) Last reviewed: 2026-04-25 Triangulated against anchor: Resveratrol (Mostly hype)

TL;DR

Three popular niche supplements consolidated on one page because the verdict is similar and the evidence base is comparably thin. Pterostilbene (resveratrol's methylated, more-bioavailable cousin), PQQ (pyrroloquinoline quinone, marketed for "mitochondrial biogenesis"), and astaxanthin (a carotenoid antioxidant) all share the pattern: striking in vitro biochemistry, modest rodent healthspan signals, very thin human evidence on aging-relevant endpoints, heavy supplement industry presence. Verdict: Mostly hype.

Pterostilbene

What it is: A dimethylated analog of resveratrol; better oral bioavailability and longer half-life. Found in blueberries. Sold at 50-250 mg/day.

Evidence:

• In vitro: similar SIRT1-engagement claims as resveratrol; same PAINS / artifact concerns plausibly apply.
• Mouse: small-scale healthspan signals; ITP not tested.
• Human: small RCTs on lipids, blood pressure show modest signals at high doses.
• No mortality, no aging-endpoint, no replication of the resveratrol-style headline findings.

Key concern: Pterostilbene is what resveratrol's commercial scenario probably should have been (better bioavailability) — but the underlying SIRT1-aging story has not held up for resveratrol, undermining the rationale for pterostilbene by analogy.

Verdict: Mostly hype.

PQQ (Pyrroloquinoline Quinone)

What it is: A redox-active quinone marketed as a "novel vitamin" promoting mitochondrial biogenesis. Sold at 10-40 mg/day.

Evidence:

• In vitro: cellular respiration / mitochondrial biogenesis effects via PGC-1α at very high concentrations; physiological relevance of the in vitro doses is debated.
• Mouse: some healthspan signals; lifespan effects single-lab and modest.
• Human: small RCTs on cognition, fatigue, lipids — short duration, surrogate endpoints, mostly null or marginal.
• No replication of headline mitochondrial-biogenesis claims at supplementation doses.

Key concern: The "vitamin" framing is marketing; PQQ is not classified as a vitamin by any major regulatory body. The mitochondrial-biogenesis claim has been contested in independent reviews.

Verdict: Mostly hype.

Astaxanthin

What it is: A xanthophyll carotenoid (the pigment in salmon, krill, certain microalgae). Strong antioxidant in vitro. Sold at 4-12 mg/day.

Evidence:

• In vitro: among the most potent natural antioxidants; lipid-soluble, distributes to mitochondrial membranes.
• Mouse: healthspan signals in disease models; lifespan effects modest and single-lab.
• Human: small RCTs on skin (UV protection), eye health, exercise recovery — modest signals on surrogates. ITP not tested.
• Some observational signal from fish-rich diets, but confounded with omega-3 and broader dietary patterns.
• No mortality or hard-endpoint longevity RCT.

Key concern: Astaxanthin is widely safe and consumed in normal diets; supplement-form claims for "longevity" rest on extrapolation from mechanistic in vitro studies and small surrogate-endpoint trials.

Verdict: Mostly hype for general longevity; possibly Suggestive for specific narrow indications (UV-induced skin aging, exercise recovery — small evidence base).

Common pattern

All three interventions exemplify the same template that resveratrol established:

1. Striking in vitro biochemistry
2. Mechanistic plausibility
3. Modest mouse healthspan / lifespan signals (single-lab)
4. Thin human RCTs on surrogate endpoints
5. No ITP testing
6. No mortality data
7. Substantial supplement industry presence
8. Marketing framing significantly outruns evidence

This is a common pattern in the longevity-supplement space and is well-described by the methodology's "Mostly hype" band.

Calibrated verdict (combined)

Mostly hype for all three, with astaxanthin possibly edging into Suggestive for narrow non-longevity indications.

Confidence interval on verdict

• Unlikely to move materially without ITP testing or large pre-registered human RCTs on hard endpoints. None imminent.

Open questions

• Q: Is any of these three being formally proposed for ITP testing?
• Q: For pterostilbene specifically, does its better bioavailability translate to in-vivo SIRT1 engagement that resveratrol fails to achieve, or does the failure persist at higher exposures?
• Q: Astaxanthin and exercise recovery — is the effect size meaningful enough to matter for chronic training adaptation?

Sources

• Polyphenols as Potential Geroprotectors (2024)
• Pterostilbene reviews — generally extending the resveratrol literature
• PQQ mitochondrial biogenesis claims — mixed independent reviews
• Astaxanthin reviews on aging / oxidative stress

Produced under methodology locked 2026-04-24. Triangulated against resveratrol anchor.